Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Brokerage Reports
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 1 - 20 ( 184 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financials Reported; Pipeline Continues Maturation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2023 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
CONTACT-02 Trial Results Presented; 2024 Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department